TrianglePUBLICATIONS · 34048275
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2021 Oct 1
- First author
- Pollard JA
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Pollard JA
- type
- Author
- name
- Guest E
- type
- Author
- name
- Alonzo TA
- type
- Author
- name
- Gerbing RB
- type
- Author
- name
- Loken MR
- type
- Author
- name
- Brodersen LE
- type
- Author
- name
- Kolb EA
- type
- Author
- name
- Aplenc R
- type
- Author
- name
- Meshinchi S
- type
- Author
- name
- Raimondi SC
- type
- Author
- name
- Hirsch B
- type
- Author
- name
- Gamis AS
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Pollard JA
- type
- Author
- name
- Guest E
- type
- Author
- name
- Alonzo TA
- type
- Author
- name
- Gerbing RB
- type
- Author
- name
- Loken MR
- type
- Author
- name
- Brodersen LE
- type
- Author
- name
- Kolb EA
- type
- Author
- name
- Aplenc R
- type
- Author
- name
- Meshinchi S
- type
- Author
- name
- Raimondi SC
- type
- Author
- name
- Hirsch B
- type
- Author
- name
- Gamis AS
- type
- Author
- bibliography ids
- nci-bib-648fd64b36013cc270a0ccde
- book metadata
- content sha256
- c1dc8d5ea0263332d83919c536face068444db06ba383149056ea851a6ef9ad3
- document type
- citation
- dois
- 10.1200/JCO.20.03048
- electronic publication date
- display
- 2021 May 28
- precision
- day
- year
- 2021
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:34048275
- immutable id
- pubmed:34048275@c1dc8d5ea0263332d83919c536face068444db06ba383149056ea851a6ef9ad3
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 28
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 3149-3160
- volume
- 39
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 34048275
- provenance
- batch id
- 79f1021053e858d13ff3
- provider
- NCBI PubMed ESummary
- record sha256
- 61191ec1232d22aa71c9d8e5fc09c488ff70132618975ab3246051648edb739d
- response sha256
- 671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
- retrieved at
- 2026-09-09T23:47:59.098265+00:00
- publication date
- display
- 2021 Oct 1
- precision
- day
- year
- 2021
- publication types
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Preserved source evidence · Independent clinical review pending · Not medical advice